fatty liver disease

Lipocine Inc (NASDAQ: LPCN) is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate. What Happened Lipocine announced top-line results from the 16-week Liver Fat Imaging study of is LPCN 1144, which showed...

Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation of fat in the liver of people who do not consume alcohol. NAFLD is a less serious condition, although non-alcoholic steatohepatitis, or NASH — a subset of NAFLD — is life-threatening, given its...